Hepatitis B virus under electron microscope. Credit: Sanofi Pasteur via Flickr.

Assembly Biosciences has completed patient enrolment in two ongoing Phase IIa trials evaluating ABI-H0731 for the treatment of chronic hepatitis B virus (HBV).

Interim data from both the ABI-H0731-201 and ABI-H0731-202 studies are expected to be available during the second quarter of this year.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Assembly Biosciences president and CEO Derek Small said: “The data from these studies will serve to inform the timelines of the HBV cure programme as well as the design of future registrational studies.

“We anticipate sharing interim data from the ongoing studies at scientific conferences this year.”

“The data from these studies will serve to inform the timelines of the HBV cure programme.”

ABI-H0731-201 is a viral antigen proof-of-concept trial that included HBeAg positive and negative patients whose viral load has exceeded on the active nucleos(t)ide (NUC) therapy.

Patients will continue to receive their NUC therapy and will be randomised in 3:2 ratio to be treated with either placebo or ABI-H0731 for a period of six months.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial aims to assess the effectiveness of ABI-H0731 in inhibiting the generation of new covalently closed circular DNA (cccDNA).

It also intends to investigate the de novo combination of ABI-H0731 and NUC therapy (entecavir) to NUC monotherapy alone.

ABI-H0731-202 is a ‘viral load’ that hired treatment-naïve HBeAg positive patients.

Once the six-month study period ends, patients will get an opportunity to rollover to an open-label combination (ABI-H0731 plus NUC) phase to receive treatment for up to one additional year.

Findings from the trial are anticipated to help create timelines and registration strategies for potent core inhibitor ABI-H0731.